Patient Guide: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 12 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06682988
Status: 🟢 Enrolling Now
Condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
Phase: PHASE2

Where You Can Participate

This study is available at 12 locations across the country.

Top locations include:
  • • Sarasota, Florida
  • • Edgewood, Kentucky
  • • Detroit, Michigan
  • • And 9 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine - Join Clinical Trial NCTNCT06682988

How to Join This Clinical Trial - NCTNCT06682988

Learn how to participate in this PHASE2 trial studying an investigational therapy for Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06682988 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 12 locations. Find a study site near you:

Clinical Research Site

Sarasota, Florida 34239 - United States

Status: RECRUITING

Clinical Research Site

Edgewood, Kentucky 41017 - United States

Status: RECRUITING

Clinical Research Site

Detroit, Michigan 48201 - United States

Status: RECRUITING

Clinical Research Site

Pittsburgh, Pennsylvania 15244 - United States

Status: RECRUITING

Clinical Research Site

Chermside, Queensland 4032 - Australia

Status: RECRUITING

Clinical Research Site

Clayton, Victoria 3168 - Australia

Status: RECRUITING

Clinical Research Site

Seongnam, Gyeonggido 13496 - Korea, Republic of

Status: RECRUITING

Clinical Research Site

Daegu, Gyeongsangbugdo 42601 - Korea, Republic of

Status: RECRUITING

Clinical Research Site

Seoul, Seoul Teugbyeolsi 03080 - Korea, Republic of

Status: RECRUITING

Clinical Research Site

Seoul, Seoul Teugbyeolsi 03722 - Korea, Republic of

Status: RECRUITING

And 2 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships